Drugs Market Research Reports & Industry Analysis

... Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes US Prostate Cancer Drug Pipeline by Clinical Phase: Research: 11 Preclinical: 44 Unknown Phase: 4 Phase 0: 1 Phase-I: 22 Phase-I/II: 18 Phase-II: 53 Phase-II/III: 1 Phase-III:14 Marketed: 13

... and new therapies would account for more than 25% of the overall market for breast cancer drug treatments. “US Breast Cancer Drug Pipeline Analysis” by ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Breast Cancer Drug Pipeline ...

... opportunity in the Breast Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Breast Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names ...

... in development phase enables the reader to identify and understand the Gene Therapy associated with the various diseases. This report enables pharmaceutical ... parameters for each drug profile in development phase are covered in “Gene Therapy Drug Pipeline Analysis” research report: Drug Profile Overview ...

... purchasing Hard Copy License depending on the location. “Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated ...

... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in France: Hospitals and Commercial Labs” is a unique study designed ...

... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Germany: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market entrants ...

... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Italy: Hospitals and Commercial Labs” is a unique study designed ...

... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Japan: Hospitals and Commercial Labs” is a unique study designed ...

... of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers” is a unique study designed to help current suppliers and potential market entrants ...

... resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs” is a unique study ...

... for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in the US: Hospitals, Commercial Labs, Physician Offices” is a unique study designed to help current suppliers and potential market ...

... a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers” is a unique study designed to help current suppliers ...

... Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the US: Hospitals, Commercial Labs, Physician Offices, ...

... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in France: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...

... Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused ... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Germany: Hospitals, Commercial Labs, Physician Offices” is a unique ...

... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Italy: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...

... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Japan: Hospitals and Commercial Labs” is a unique market and ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...

... preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in Spain: Hospitals, Commercial Labs, Ambulatory Care Centers” ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. ...

... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs” is a unique ... responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors ...

... Acid and Vancomycin. During the next five years, the TDM market will undergo significant transformation. These changes will be caused ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market in the US: Hospitals, Commercial Labs, Physician Offices” ...

... Group contains 14 tables, and provides a comprehensive analysis of the POC drugs of abuse testing market, including trends, dynamics, size, growth, regulatory ... . Five-year test volume and reagent sales forecasts for drugs of abuse procedures by market segment: Physician Offices/Group Practices Emergency ...

... brand images. Compared with that of countries with advanced medicine levels, China OTC drug industry is featured by late start, fast growth and ... or occupy market by regional advantages. With the standardizing development of domestic OTC drug market and the increase in residents' healthcare consciousness, the ...

... shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for ... , such as specimen preparation devices, controls, calibrators and others. “2013 Drugs of Abuse Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan” ...

... shares) $5,500. This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic ... as specimen preparation devices, controls, calibrators and others. “2013 Therapeutic Drug Monitoring (TDM) Market: US, Europe (France, Germany, Italy, Spain, UK), Japan” ...

... as extensive listings of companies developing and marketing innovative technologies and products. This report also presents strategic assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, new ...

... their dynamics, trends, structure, size, growth and major suppliers. Five-year test volume and reagent sales forecasts for drugs of ... Offices/Group Practices Emergency Rooms Ambulatory Care Centers Analysis of drugs of abuse procedures Competitive Assessments Assessments of major POC suppliers and ...

... impact of the economic downturn in Europe and the United States, China’s future vitamin market will face grim situation, especially exports even ... also with average export prices lifted to varying degrees . China Vitamin Industry Report, 2012-2015 of ResearchInChina mainly covers the followings: International ...

Product description The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the ...

Product description The Competitive Intelligence Report Insulin as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant insulin and in...

Product description The Competitive Intelligence Report Interferon as of April 2014 provides a competitor analysis in the product portfolios and development pipelines of novel recombinant and natural...

... in 2018. Lucintel, a leading global management consulting and market research firm, has analyzed the global oncology drugs industry and presents its findings in Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis. The industry comprises firms primarily engaged in the development, manufacture, and marketing of oncology drugs. Lucintels ...

... Five Global Generic Drug Companies Performance, Strategies, and Competitive Analysis. The report provides detailed insight into the performance of the top five generic drug companies ... the market share for generic drugs. This study provides industry leaders with a competitive benchmarking of the worlds top five generic drug companies. The study ...

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion ... patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China’s anti-PH drug market is very bright. The annual growth rate ...

... the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared ... market development also accelerates. Although the overall market size of China's anti-AD drug market is relatively small, the growth rate is always ...

... analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put ... . The report highlights the followings: Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc. China insulin ...

... , a leading global management consulting and market research firm, has analyzed the global diabetes drugs industry and presents its findings in “Global Diabetes Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis.” The diabetes drugs industry is highly consolidated with all classes of drugs ...

... from Venture Planning Group contains 311 pages and 61 tables. 'Drugs of Abuse Testing Market: US, Europe, Japan' is a unique study designed to help current ... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ...

... , with the increasing recognition rate of doctors for depression and people's changes in treatment concepts, it is expected that the future potential of China's antidepressant market is fairly great. It is predicted that in coming years, the annual growth rate of market size of China's antidepressants in ...

... of fungi increasingly enhances, so it indicates a sharply rising trend for the clinical application of antifungal drugs. It is expected that in coming years, the annual growth rate of market size of China's antifungal drugs will be over 20%. As for manufacturers, there are many opportunities. ...

... aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached ... the market positions of insulin preparations and Acarbose. The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from ...

... , the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients ... aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The ...

... a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis ... to provide industry leaders with a competitive benchmarking of the world’s top five cardiovascular drugs companies. The study provides up-to-date information on the market share ...

... , the overall morbidity rate of dyslipidemia groups aged 18 and above is over 20% in China, and total patients are over 200 million nationwide. Blood ... , thus occupying a most advantageous position clinically. The overall performance of China's hypolipidemic drugs in the drug market is better than that of the ...

... pts – GT1, Null, and Naïve seems to have become the norm. At AASLD 2012: (i) GILD presented interim data from the ongoing PhII ... , please read our report released on 20th Nov. 2012, titled, 'Hepatitis C: UPDATE Post AASLD ’12 - Progress in IFN-Free Drugs & Vaccines - Gilead and Abbott vying ...

... five years, from 2012-2017, will see the launch of many new drugs. Scope of the Report The Alzheimer’s drug market (2011-2017) ... III clinical trials. Chapter 8 provides profiles of the key companies in this market. Each company profile includes information such as financial performance, geographical ...

... Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report ...

... is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman ...

... clinical significance and market needs for major current and emerging NAT assays, as well as extensive listings of companies developing and marketing ... . This report also presents strategic assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios ...

... This report provides you concise information about the vitamin B2 industry in China, discovering not only the latest dynamics of production situation and producers ... , but also price, import and export, and the application fields of the vitamin B2 products. Besides, ...